Gerresheimer’s €870 Million Debt Lifeline Buys Time as Audit Deadline and Regulatory Probes Intensify

Pharma packaging group Gerresheimer battles trust crisis with premature revenue bookings, regulatory investigations, and a critical June audit deadline for its financial statements.

The clock is ticking for Gerresheimer on two fronts: a June deadline for audited financial statements and a raft of regulatory investigations that threaten to overshadow any operational progress. The pharma packaging group secured a critical reprieve last month when Schuldschein holders agreed to a maturity extension on €870 million of debt and temporarily waived key covenants, but the fundamental question of trust in its accounting remains unanswered.

At the heart of the crisis are systematic revenue-recognition failures tied to Bill-and-Hold transactions. An independent law firm confirmed that Gerresheimer booked €35 million in revenue prematurely, along with €24 million in adjusted EBITDA, in violation of IFRS rules. The fallout has widened to include €65.5 million in incorrectly reported lease liabilities and misstated development cost amortisation. The BaFin launched a probe on 6 March 2026 specifically examining potential impairments of €196.5 million in the Advanced Technologies segment, while the audit oversight body APAS is investigating KPMG for giving an unqualified opinion on the 2024 accounts despite the disputed transactions.

The company has since brought in Grant Thornton as a second auditor to restore credibility, hoping to secure a clean opinion on the upcoming annual report. But the market remains sceptical: the short interest stands at roughly 11.4%, and the stock closed Friday at €24.96, now 8.64% lower on the week and well below its 200-day moving average of €27.37. Over the past year, Gerresheimer shares have shed 60% of their value.

Amid the turmoil, some insiders are betting on a turnaround. Active Ownership Fund, the Luxembourg-based activist investor, raised its stake from 14.70% to 15.19% in early May, and combined insider purchases by executives and major holders reached nearly €9.7 million. Those moves signal conviction from those closest to the business, though analysts note they do not erase the accounting overhang.

Operationally, Gerresheimer is pushing ahead with restructuring. The company has rejected a takeover offer from US competitor Silgan and is instead pursuing the sale of its US subsidiary Centor Inc., a maker of packaging systems for prescription drugs, with Morgan Stanley advising. The transaction is expected to close this year, although divesting a higher-margin unit could dent overall profitability. At the same time, the glass plant in Chicago Heights will close by the end of 2026, eliminating 172 jobs, with production moving to Italy and India. On the innovation side, Gerresheimer announced a partnership with Milliken & Company at Interpack in Düsseldorf for LeneX™ UltraGuard®, an additive technology that improves moisture barriers in HDPE packaging by up to 40%.

The management maintains its full-year guidance: adjusted EBITDA margin of 18% to 19% and moderately positive free cash flow. Those targets, however, hang on the outcome of the June audit. The company plans to release the audited annual report and first-quarter results next month, followed by the half-year report on 14 July and third-quarter numbers on 15 October. A date for the postponed annual general meeting has yet to be set.

For now, every rally in Gerresheimer shares is tested against the €27.37 technical resistance. A break above that level would signal renewed momentum, but without the clarity of a clean audit, any recovery remains fragile. The €870 million debt extension gives breathing room, but the credibility gap is narrowing fast.